Biogen Inc (BIIB)

318.46
NASDAQ : Health Care
Prev Close 315.03
Day Low/High 311.30 / 319.34
52 Wk Low/High 244.28 / 330.00
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 211.43M
Market Cap 66.61B
EPS 17.00
P/E Ratio 20.67
Div & Yield N.A. (N.A)

Latest News

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Biogen Reports New Data From Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab

Biogen Reports New Data From Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab

Biogen (NASDAQ: BIIB) today announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company's investigational treatment for early...

IMRALDI®, Biogen's Adalimumab Biosimilar Referencing Humira®, Is Approved In The European Union

IMRALDI®, Biogen's Adalimumab Biosimilar Referencing Humira®, Is Approved In The European Union

The European Commission (EC) granted a marketing authorization for IMRALDI ® (also known as SB5), an adalimumab biosimilar referencing Humira ®.

European Pharma Companies Slip on MS Pricing Probe

European Pharma Companies Slip on MS Pricing Probe

House Democrats start probe into MS drug prices

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

'Biogen has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow.'

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire

All eyes are on Pfizer in the months ahead.

Pfizer's Weak Viagra, Consumer Sales Drag Down Massive Gains in New Products

Pfizer's Weak Viagra, Consumer Sales Drag Down Massive Gains in New Products

Pfizer post earnings beat.

Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences

Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences

Biogen (NASDAQ:BIIB) today announced the appointment of Anabella Villalobos, Ph.

Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies

Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies

The agreement is the first to apply value-based contracts to cover Medicaid patients in the United States.

Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies

Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies

The agreement is the first to apply value-based contracts to cover patients in Puerto Rico.

United Therapeutics, DOJ in Possible Settlement Over Drug Contributions

United Therapeutics, DOJ in Possible Settlement Over Drug Contributions

The Justice Department is investigating the company's charitable contributions for kickbacks and false claims.

Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records

Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records

Wall Street at records.

Closing Bell: S&P 500 at Record; Senate Passes Motion to Proceed on Healthcare

Closing Bell: S&P 500 at Record; Senate Passes Motion to Proceed on Healthcare

The S&P 500 and Nasdaq end at records.

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite

Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25.

S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq

S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq

Stocks are mixed.

4 Stocks Warren Buffett Would Love

4 Stocks Warren Buffett Would Love

These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.

Stock Futures Solidly Higher but Alphabet's Earnings Cause Concern

Stock Futures Solidly Higher but Alphabet's Earnings Cause Concern

Stock futures are higher.

The Dow Binges on Earnings

The Dow Binges on Earnings

Get ready for another heavy earnings slate

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens

U.S. stock futures turn higher on Tuesday following earnings from Alphabet.

Biogen Reports Record Quarterly Revenues Of $3.1 Billion, Raises Full Year Revenue Guidance

Biogen Reports Record Quarterly Revenues Of $3.1 Billion, Raises Full Year Revenue Guidance

Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2017 financial results, including: Total revenues of $3.

Alisha A. Alaimo Appointed SVP Of Biogen's US Therapeutic Operations

Alisha A. Alaimo Appointed SVP Of Biogen's US Therapeutic Operations

Biogen (NASDAQ: BIIB) announced today the appointment of Alisha A.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Here are the activist investor's next potential targets.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Biogen To Present Data At Alzheimer's Association International Conference® 2017 (AAIC®)

Biogen To Present Data At Alzheimer's Association International Conference® 2017 (AAIC®)

Biogen (NASDAQ: BIIB) will present data from its Alzheimer's disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

TheStreet Quant Rating: B (Buy)